Dr. Barbara Klencke, Chief Development Officer, Sierra Oncology talks about the development of momelotinib for myelofibrosis, a rare blood cancer.  Momelotinib's unique mechanism of action allows it to address all three key symptoms of myelofibrosis, including the debilitating anemia which can be exacerbated by currently available therapies.  The Phase 3 MOMENTUM Clinical Trial evaluating momelotinib for patients with MF is currently recruiting globally.  To learn more: momentumtrial.com #myelofibrosis #JAKInhibitor #ClinicalTrial #RareCancer SierraOncology.com Download the transcript here